Submitted: 02 Aug 2011
EndNote EndNote

(Enw Format - Win & Mac)

BibTeX BibTeX

(Bib Format - Win & Mac)

Bookends Bookends

(Ris Format - Mac only)

EasyBib EasyBib

(Ris Format - Win & Mac)

Medlars Medlars

(Txt Format - Win & Mac)

Mendeley Web Mendeley Web
Mendeley Mendeley

(Ris Format - Win & Mac)

Papers Papers

(Ris Format - Win & Mac)

ProCite ProCite

(Ris Format - Win & Mac)

Reference Manager Reference Manager

(Ris Format - Win only)

Refworks Refworks

(Refworks Format - Win & Mac)

Zotero Zotero

(Ris Format - FireFox Plugin)

J Cardiovasc Thorac Res. 2011;3(4):113-116.
doi: 10.5681/jcvtr.2011.025
PMID: 24250967
PMCID: PMC3825338
  Abstract View: 612
  PDF Download: 644

Original Article

The Twelve-Month Outcome of Biolimus Eluting Stent with Biodegradable Polymer Compared With an Everolimus Eluting Stent with Durable Polymer

Abstract

Introduction Drug-eluting stents (DES) have significantly decreased the need for repeat coronary revascularization but concerns remain regarding the safety of first and second generation DES. We compared the safety and efficacy of a biolimus-eluting stent (with biodegradable polymer) with an everolimus-eluting stent (with durable polymer) one. Me-thods: We performed a randomized trial to compare the two types of stents. Two hundred patients undergoing PCI for de novo lesions were randomly assigned 1:1 to treatment with either biolimus-eluting (BioMatrix) or everolimus -eluting (Xience V) stent. The primary endpoint was a composite of cardiac death, myocardial infarction, and clinically driven target vessel revascularization within 12 months. Results: Demographics, clinical, and lesion characteristic were comparable between two groups. The 30-day major adverse car-diac event (MACE) rate was 2% in BioMatrix group versus 0% in Xience group (p > 0.05). After 12 months, the rates of cardiac death (0% in both groups), MI (2% versus 0%, p=0.49) and clinically –driven target vessel revascularization (0% in both groups) were similar for BioMatrix and Xience. No stent thrombosis was reported at 1, 6, 9 or 12 months after intervention in either group. Conclusion: BES (Biolimus-eluting stent) with biodegradable polymer and EES (Everolimus-eluting stent) with durable polymer appear similar with respect to MACE and stent thrombosis in this patient population. Many stu-dies with longer follow up are needed to define better the role of BES with biodegradable polymer in treatment of coronary artery lesions.
First name
 
Last name
 
Email address
 
Comments
 
Security code


Article Viewed: 612

Your browser does not support the canvas element.


PDF Downloaded: 644

Your browser does not support the canvas element.